| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| Other Sizes |
Purity: =99.29%
PSMA-11 (HBED-CC-PSMA or Psma-hbed-CC) can be used to prepare gallium Ga 68-labeled PSMA-11, which has potential use as a tracer for PSMA-expressing tumors during positron emission tomography (PET). Upon intravenous administration of gallium Ga 68-labeled PSMA-11, the Glu-urea-Lys(Ahx) moiety targets and binds to PSMA-expressing tumor cells. Upon internalization, PSMA-expressing tumor cells can be detected during PET imaging. PSMA, a tumor-associated antigen and type II transmembrane protein, is expressed on the membrane of prostatic epithelial cells and overexpressed on prostate tumor cells
| References |
: Meißner S, Janssen JC, Prasad V, Brenner W, Diederichs G, Hamm B, Hofheinz F, Makowski MR. Potential of asphericity as a novel diagnostic parameter in the evaluation of patients with (68)Ga-PSMA-HBED-CC PET-positive prostate cancer lesions. EJNMMI Res. 2017 Oct 23;7(1):85. doi: 10.1186/s13550-017-0333-9. PubMed PMID: 29058157; PubMed Central PMCID: PMC5651532.
|
|---|---|
| Additional Infomation |
Gorzetide is an unlabeled radiotracer composed of a human prostate-specific membrane antigen (PSMA) targeting ligand linked to an acyclic radiometal chelator, N,N'-bis[2-hydroxy-5-(carboxyethyl)benzyl]ethylenediamine-N,N'-diacetic acid (HBED-CC), and may be used to prevent or reduce salivary gland toxicity caused by PSMA-targeted radionuclides. Injection of Gorzetide into the salivary glands selectively reduces the uptake of systemically administered PSMA-targeted radionuclides in saliva. This may reduce salivary gland toxicity caused by these drugs, including salivary gland hypofunction and xerostomia.
Drug Indications This drug is for diagnostic use only. Locametz, after being radiolabeled with gallium-68, is indicated for the detection of prostate-specific membrane antigen (PSMA)-positive lesions in adult patients with prostate cancer (PCa) via positron emission tomography (PET) in the following clinical settings: initial staging of high-risk PCa patients before radical treatment; screening for suspected PCa recurrence in patients with elevated serum PSA levels after radical treatment; and identification of patients with PSMA-positive progressive metastatic castration-resistant prostate cancer (mCRPC) who require PSMA-targeted therapy (see Section 4.4). |
| Molecular Formula |
C44H62N6O17
|
|---|---|
| Molecular Weight |
947.005
|
| Exact Mass |
946.417
|
| Elemental Analysis |
C, 55.81; H, 6.60; N, 8.87; O, 28.72
|
| CAS # |
1366302-52-4
|
| Related CAS # |
2412149-32-5 (TFA);1366302-52-4;PSMA-11 HCl;
|
| PubChem CID |
60143283
|
| Appearance |
White to off-white solid powder
|
| Density |
1.4±0.1 g/cm3
|
| Boiling Point |
1275.1±65.0 °C at 760 mmHg
|
| Flash Point |
725.0±34.3 °C
|
| Vapour Pressure |
0.0±0.3 mmHg at 25°C
|
| Index of Refraction |
1.602
|
| LogP |
0.2
|
| Hydrogen Bond Donor Count |
12
|
| Hydrogen Bond Acceptor Count |
19
|
| Rotatable Bond Count |
35
|
| Heavy Atom Count |
67
|
| Complexity |
1620
|
| Defined Atom Stereocenter Count |
2
|
| SMILES |
OC1C=CC(CCC(NCCCCCC(NCCCC[C@@H](C(=O)O)NC(N[C@H](C(=O)O)CCC(=O)O)=O)=O)=O)=CC=1CN(CC(=O)O)CCN(CC(=O)O)CC1C(=CC=C(CCC(=O)O)C=1)O
|
| InChi Key |
QJUIUFGOTBRHKP-LQJZCPKCSA-N
|
| InChi Code |
InChI=1S/C44H62N6O17/c51-34-13-8-28(22-30(34)24-49(26-40(59)60)20-21-50(27-41(61)62)25-31-23-29(9-14-35(31)52)11-16-38(55)56)10-15-37(54)46-18-4-1-2-7-36(53)45-19-5-3-6-32(42(63)64)47-44(67)48-33(43(65)66)12-17-39(57)58/h8-9,13-14,22-23,32-33,51-52H,1-7,10-12,15-21,24-27H2,(H,45,53)(H,46,54)(H,55,56)(H,57,58)(H,59,60)(H,61,62)(H,63,64)(H,65,66)(H2,47,48,67)/t32-,33-/m0/s1
|
| Chemical Name |
(3S,7S)-22-(3-(((2-((5-(2-Carboxyethyl)-2-hydroxybenzyl)(carboxymethyl)amino)ethyl)(carboxymethyl)amino)methyl)-4-hydroxyphenyl)-5,13,20-trioxo-4,6,12,19-tetraazadocosane-1,3,7-tricarboxylic acid
|
| Synonyms |
Psma-hbed-CC PSMA-11 PSMA11 PSMA 11 HBED-CC-PSMA.
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~105.60 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (2.64 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (2.64 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (2.64 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.0560 mL | 5.2798 mL | 10.5596 mL | |
| 5 mM | 0.2112 mL | 1.0560 mL | 2.1119 mL | |
| 10 mM | 0.1056 mL | 0.5280 mL | 1.0560 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA